Related Experiment Video
Updated: Jun 20, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
Pharmacologic p53 activation blocks cell cycle progression but fails to induce senescence in epithelial cancer cells
Baoying Huang1, Dayanand Deo, Mingxuan Xia
1Discovery Oncology, Hoffmann-La Roche, Inc., Nutley, NJ 07110, USA.
Abstract:
Cellular senescence is a stress-induced state of irreversible growth arrest thought to act as a barrier to cancer development. The p53 tumor suppressor is a critical mediator of senescence and recent in vivo studies have suggested that p53-induced senescence may contribute to tumor clearance by the immune system. Recently developed MDM2 antagonists, the nutlins, are effective p53 activators and potent antitumor agents in cells with functional apoptotic pathways. However, they only block cell cycle progression in cancer cells with compromised p53 apoptotic signaling. We use nutlin-3a as a selective probe to study the role of p53 activation in senescence using a panel of eight epithelial cancer cell lines and primary epithelial cells. Our results reveal that the MDM2 antagonist can induce a senescence-like state in all tested cell lines, but it is reversible and cells resume proliferation upon drug removal and normalization of p53 control. Retinoblastoma family members (pRb, p107, and p130) previously implicated in gene silencing during fibroblasts senescence were found down-regulated in cells with nutlin-induced senescence-like phenotype, suggesting a mechanism for its reversibility. Therefore, selective p53 pathway activation is insufficient for induction of true senescence in epithelial cells in vitro. However, elevated expression of several inflammatory cytokines in cancer cells with nutlin-induced senescence-like phenotype suggests a possible in vivo benefit of p53-activating therapies.
Insights
MDM2 antagonists activate p53 but induce only reversible senescence in epithelial cancer cells. This suggests p53 activation alone is insufficient for true senescence, though it may offer in vivo benefits via inflammatory cytokines.
Area of Science:
- Oncology
- Cell Biology
- Molecular Biology
Background:
- Cellular senescence, a state of irreversible growth arrest, acts as a tumor suppressor mechanism.
- The p53 tumor suppressor is crucial for inducing senescence and potentially aiding tumor clearance by the immune system.
- MDM2 antagonists (nutlins) activate p53 but are effective antitumor agents only in cancer cells with intact apoptotic pathways.
Purpose of the Study:
- To investigate the role of p53 activation in inducing cellular senescence in epithelial cancer cells using the MDM2 antagonist nutlin-3a.
- To determine if selective p53 pathway activation is sufficient for inducing stable, irreversible senescence in epithelial cells.
- To explore the potential in vivo therapeutic benefits of p53-activating therapies.
Main Methods:
- Utilized nutlin-3a as a selective p53 activator.
- Tested nutlin-3a on a panel of eight epithelial cancer cell lines and primary epithelial cells.
- Analyzed the reversibility of the induced senescence-like state and changes in retinoblastoma family proteins (pRb, p107, p130).
- Assessed the expression of inflammatory cytokines in treated cells.
Main Results:
- Nutlin-3a induced a senescence-like state in all tested epithelial cells, but this state was reversible upon drug removal.
- Retinoblastoma family members (pRb, p107, p130), crucial for senescence, were downregulated in cells with the nutlin-induced phenotype, explaining its reversibility.
- Selective p53 activation by nutlin-3a was insufficient to induce true, irreversible senescence in vitro.
- Elevated expression of inflammatory cytokines was observed in cancer cells with the nutlin-induced senescence-like phenotype.
Conclusions:
- Selective p53 pathway activation is insufficient to establish true senescence in epithelial cells in vitro.
- The reversibility of nutlin-induced senescence is linked to the downregulation of retinoblastoma family proteins.
- Despite the lack of stable senescence induction in vitro, p53-activating therapies may hold therapeutic potential in vivo due to the induction of inflammatory cytokines.
Related Concept Videos
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Abnormal Proliferation
Negative Regulator Molecules
Inhibition of Cdk Activity
Molecular Factors Affecting Cell Division
Several proteins function as internal regulators to ensure each cell cycle stage is completed faithfully before proceeding to the next. Regulator molecules may act directly or influence the activity or production of other...
